Core Viewpoint - The article discusses a class action lawsuit against NuScale Power Corporation, alleging that the company and its executives made misleading statements regarding their commercialization partnership with ENTRA1 Energy LLC, which has resulted in significant financial losses for investors [1][3]. Group 1: Class Action Lawsuit Details - Investors who purchased NuScale Class A common stock between May 13, 2025, and November 6, 2025, can seek appointment as lead plaintiff by April 20, 2026 [1]. - The lawsuit, titled Truedson v. NuScale Power Corporation, accuses NuScale and its executives of violating the Securities Exchange Act of 1934 [1]. - The lawsuit claims that NuScale's reliance on ENTRA1, which has no significant experience in nuclear power projects, poses undisclosed risks to its commercialization strategy [3]. Group 2: Financial Impact - On November 6, 2025, NuScale reported a more than 3,000% increase in general and administrative expenses, rising to $519 million from $17 million in the previous year, primarily due to a $495 million payment to ENTRA1 [4]. - The company's quarterly net loss surged to $532 million, compared to $46 million in the prior year [4]. - Following the financial disclosures, NuScale's Class A share price dropped over 12% within two days [4]. Group 3: Company Background and Legal Representation - NuScale's core technology, the NuScale Power Module, is designed for energy generation within a broader power plant context [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, has a strong track record in prosecuting investor class actions, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - A securities fraud class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly making materially false statements and failing to disclose adverse facts about its business and operations during the specified class period [2][4]. Summary by Relevant Sections Lawsuit Details - The class action lawsuit is on behalf of investors who purchased PayPal common stock between February 25, 2025, and February 2, 2026 [2][6]. - Investors have until April 20, 2026, to file for lead plaintiff status [2][6]. Allegations - The complaint alleges that PayPal's management misrepresented the company's revenue outlook and growth potential while downplaying risks associated with seasonality and macroeconomic factors [4][6]. - PayPal's growth initiatives, particularly regarding its Branded Checkout offerings, were claimed to be unrealistic and not achievable under the current CEO's leadership [4]. Stock Performance - Following a surprise leadership change and a disappointing earnings report on February 3, 2026, PayPal's stock price dropped by $10.63, or 20.3%, closing at $41.70 per share [5]. Investor Actions - Investors can seek to be appointed as lead plaintiffs or choose to remain absent class members [6][8]. - Kessler Topaz Meltzer & Check, LLP offers free case evaluations and operates on a contingency fee basis [7][10].

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab during clinical trials [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc. and covers purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on Osteogenesis Imperfecta patients and downplayed the risks associated with the Phase III Orbit study [3]. Group 2: Study Results and Stock Impact - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - On December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a further stock price decline of more than 42% [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ultragenyx stock during the class period to seek lead plaintiff status, representing the interests of the class [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - Navan, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO documents, which led to significant financial losses for investors [1] Group 1: Class Action Lawsuit Details - The class action lawsuit, titled McCown v. Navan, Inc., was initiated against Navan and its executives for violations of the Securities Act of 1933 [1] - Investors who purchased shares during Navan's IPO on October 31, 2025, at an offering price of $25.00 per share, have until April 24, 2026, to seek appointment as lead plaintiff [1] - The lawsuit claims that Navan's offering documents failed to disclose a planned 39% increase in sales and marketing expenses shortly after the IPO [1] Group 2: Financial Impact - Following the disclosure of increased sales and marketing expenses to nearly $95 million, a 39% rise from $68.5 million in the previous quarter, Navan's stock price fell nearly 12% [1] - The stock price has since declined to as low as $9.20 per share, representing a nearly 63% drop from the IPO price [1] Group 3: Company Overview - Navan operates an AI-powered software platform aimed at simplifying travel and expense management for users, customers, and suppliers [1] - The firm Robbins Geller Rudman & Dowd LLP, which is leading the class action, is recognized as a top law firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]

Core Viewpoint - Soleno Therapeutics Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to undisclosed safety concerns regarding its product DCCR, which is intended for treating hyperphagia in Prader-Willi syndrome patients [1]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc." and covers investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 [1]. - Investors have until May 5, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [1]. Group 2: Allegations and Impact - The lawsuit claims that the Phase 3 clinical trial program for DCCR misrepresented safety evidence, leading to greater risks than disclosed [1]. - Following a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell nearly 12% over two trading days [1]. - After a patient death was reported on September 10, 2025, the stock price declined approximately 19% over two trading days [1]. - On November 4, 2025, Soleno reported a disruption in DCCR's launch trajectory, resulting in a further 27% decline in stock price [1]. Group 3: Company Background - Soleno Therapeutics is a biopharmaceutical company focused on developing therapeutics for rare diseases, with DCCR as its only commercial product [1]. - The company is currently facing significant challenges regarding the commercial viability of DCCR due to the allegations and subsequent stock price declines [1].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. for allegedly misleading investors regarding its Huntington's disease gene therapy drug AMT-130 during the class period from September 24, 2025, to October 31, 2025 [1][2] Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1] - Investors who purchased uniQure ordinary shares during the class period may seek to serve as lead plaintiff by April 13, 2026 [1] Allegations - The complaint alleges that uniQure made materially false and misleading statements about its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [1] - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its BLA submission [1] Impact on Share Price - On November 3, 2025, uniQure's share price dropped by $33.40, or over 49%, from $67.69 to $34.29 per share after the company disclosed that the FDA did not agree that the data from the Phase I/II studies was adequate for BLA submission [1] Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing to be lead plaintiff by the deadline [1] - The lead plaintiff process allows investors to represent the class in litigation, with the potential for recovery not affected by the decision to serve as lead plaintiff [1]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and certain senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][4]. Company Overview - Ardent Health operates acute care hospitals and other healthcare facilities, with a focus on the collection of accounts receivable [5]. Allegations - The lawsuit claims that Ardent Health misrepresented its collection practices, stating it relied on "detailed reviews of historical collections" when, in fact, it used a "180-day cliff" method for determining account collectability, leading to inflated accounts receivable figures [5]. - The alleged misrepresentations are said to violate federal securities laws [5]. Stock Performance - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, resulting in a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 on November 13, 2025 [6][9]. Legal Proceedings - Investors have until March 9, 2026, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, under the caption Postiwala v. Ardent Health, Inc., et al. [4][9].

Core Viewpoint - A class action lawsuit has been filed against NuScale Power Corporation and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - Investors have until April 20, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Oregon [4][10]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in NuScale Class A common stock [4][10]. Group 2: Allegations Against NuScale - NuScale is accused of misrepresenting the capabilities and experience of ENTRA1 Energy LLC, which was supposed to construct power generation facilities using NuScale's technology [5][10]. - ENTRA1 was portrayed as a well-established independent power plant development platform, but it allegedly had no significant experience in building or operating nuclear power projects [6][7]. Group 3: Stock Performance Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses from $17 million to $519 million, primarily due to a $495 million payment to ENTRA1 [8]. - Following the disclosure of ENTRA1's lack of experience, NuScale's stock dropped by $4.03 per share, or over 12.4%, from $32.46 to $28.43 between November 6 and November 10, 2025 [8][10].

Core Viewpoint - The Soleno Therapeutics, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to the safety and commercial viability of its product DCCR for treating hyperphagia in Prader-Willi syndrome patients [1][3]. Company Overview - Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with its only commercial product being diazoxide choline extended-release tablets (DCCR) [2]. Allegations of the Lawsuit - The lawsuit claims that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [3]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks of adverse events post-launch [3]. Impact of External Reports - On August 15, 2025, a critical report by Scorpion Capital LLC led to a nearly 12% decline in Soleno's stock price over two trading days [4]. - Following a report of a patient death associated with DCCR on September 10, 2025, Soleno's stock price dropped approximately 19% over two trading days [5]. - The financial results reported on November 4, 2025, indicated a "disruption" in DCCR's launch trajectory, resulting in a further 27% decline in stock price [6]. Legal Process - Investors who purchased Soleno common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of all class members [7]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [8]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [9].

Core Viewpoint - Eos Energy Enterprises, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with significant financial losses reported during the Class Period from November 5, 2025, to February 26, 2026 [1][3]. Company Overview - Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems for utility-scale commercial and industrial applications [2]. Allegations of the Lawsuit - The lawsuit claims that Eos Energy made false or misleading statements and failed to disclose critical operational issues, including: - Inability to achieve production and capacity utilization as per guidance [3]. - Battery line downtime exceeding industry norms and internal forecasts [3]. - Delays in automated bipolar production quality targets [3]. - Inadequate systems preventing accurate guidance and timely disclosures [3]. Financial Performance - On February 26, 2026, Eos Energy reported its fourth quarter and full year 2025 results, revealing: - Full year 2025 revenue of $114.2 million, significantly below the guidance of $150 million to $160 million [4]. - A gross loss of $143.8 million and a net loss attributable to shareholders of $969.6 million [4]. - An adjusted EBITDA loss of $219.1 million and a capacity milestone reached five weeks later than planned [4]. - Following this announcement, Eos Energy's stock price fell by more than 39% [4]. Legal Process - Investors who purchased Eos Energy securities during the Class Period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5].